Cargando…

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Purpose. To evaluate the early response to intravitreal ranibizumab (IVR) in two different phenotypes of age-related macular degenerations (AMD): typical neovascular AMD (tAMD) and polypoidal choroidal vasculopathy (PCV). Methods. Sixty eyes from 60 patients (tAMD 28, PCV 32 eyes) were recruited. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumiya, Wataru, Honda, Shigeru, Bessho, Hiroaki, Kusuhara, Sentaro, Tsukahara, Yasutomo, Negi, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136135/ https://www.ncbi.nlm.nih.gov/pubmed/21772985 http://dx.doi.org/10.1155/2011/742020

Ejemplares similares

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
por: Matsumiya, Wataru, et al.
Publicado: (2013)

The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration
por: Bessho, Hiroaki, et al.
Publicado: (2012)

Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy
por: Honda, Shigeru, et al.
Publicado: (2012)

Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2)
por: Yanagisawa, Suiho, et al.
Publicado: (2011)

The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Bessho, Hiroaki, et al.
Publicado: (2011)

SOD2 gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Kondo, Naoshi, et al.
Publicado: (2009)

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
por: Honda, Shigeru, et al.
Publicado: (2010)

Coding variant Met72Thr in the PEDF gene and risk of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Bessho, Hiroaki, et al.
Publicado: (2009)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

A Case of Bilateral Macular Holes Showing Onset and Spontaneous Closure over Very Short Intervals
por: Matsumiya, Wataru, et al.
Publicado: (2010)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

The Association of Elastin Gene Variants with Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy
por: Yanagisawa, Suiho, et al.
Publicado: (2015)

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response
por: Hatz, Katja, et al.
Publicado: (2014)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

A Common Complement C3 Variant Is Associated with Protection against Wet Age-Related Macular Degeneration in a Japanese Population
por: Yanagisawa, Suiho, et al.
Publicado: (2011)

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
por: Sakurai, Madoka, et al.
Publicado: (2014)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy
por: Liu, Ling, et al.
Publicado: (2015)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Yoneyama, Seigo, et al.
Publicado: (2020)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
por: Lai, Kunbei, et al.
Publicado: (2018)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
por: Azuma, Keiko, et al.
Publicado: (2020)

A Comparative Study of Choroidal Vascular and Structural Characteristics of Typical Polypoidal Choroidal Vasculopathy and Polypoidal Choroidal Neovascularization: OCTA-Based Evaluation of Intervortex Venous Anastomosis
por: Batıoğlu, Figen, et al.
Publicado: (2022)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
por: Tamachi, Tomoko, et al.
Publicado: (2020)

Prevalence of Polypoidal Choroidal Vasculopathy in Eyes with Neovascular Age-Related Macular Degeneration Resistant to Intravitreal Anti-VEGF Treatment
por: Menteş, Jale, et al.
Publicado: (2022)

Polypoidal Choroidal Vasculopathy Associated with Optic Disc Coloboma
por: Nakano, Yumiko, et al.
Publicado: (2018)

One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
por: Kitagawa, Yorihisa, et al.
Publicado: (2022)

Outcome of Peripapillary Polypoidal Choroidal Vasculopathy Treatment using Combination Therapy Intravitreal Ranibizumab and Thermal Retinal Laser Photocoagulation
por: Okonkwo, Ogugua Ndubuisi, et al.
Publicado: (2023)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2021)

Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7mn2nmpdr5vt4fjgpr2pd1ruem